/

VIR

Vir Biotechnology, Inc.Open

11.03−0.28 −2.43%USD

NasdaqGS · as of Oct 13, 11:22 ET · 15m delay

Open

11.21

Prev close

11.30

Day range

11.0111.25

52-week range

4.8212.00

Volume

369.64K0.19×

Mkt cap

1.87B

P/E ttm

—

Fwd P/E

-4.43

EPS ttm

-1.76

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−8.12%

Price Chart

Yahoo Finance · delayed

VIROct 13, 2026O 11.21H 11.24L 11.01C 11.02−0.28 (−2.43%)Vol 369.64K

SMA 5010.51
SMA 2009.21

1Y change +90.09% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VIR Vir Biotechnology, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.96%
1 month: +3.81%
3 months: +16.17%
6 months: +9.70%
Year to date: +82.84%
1 year: +88.14%

Valuation & ownership

Market cap: 1.87B
Enterprise value: 1.47B
P/E (ttm): —
Forward P/E: -4.43
PEG ratio: —
Price / book: 1.90
Price / sales (ttm): 6.15
EV / EBITDA: -5.50
EPS (ttm): -1.76
EPS (forward): -2.49
Beta (5y monthly): 1.59
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 169.22M
Float: 129.82M
Short % of float: 8.96%
Short ratio (days): 6.87
Held by insiders: 6.57%
Held by institutions: 84.36%
Avg volume (3m): 1.92M
50-day average: 10.47
200-day average: 9.19
52-week change: +88.14%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 50.3
vs 50-day SMA: +4.92%
vs 200-day SMA: +19.70%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.59%
Realised vol (20d, ann.): 51.7%
From 52-week high: −8.13%
From 52-week low: +128.97%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.30 on a 1 (strong buy) – 5 (sell) scale

Mean target

21.00

+90.48% implied

Low 15.00Median 21.00High 30.00

Recommendation trend

Now10 / 0 / 0
1m ago10 / 0 / 0

DES

About Vir Biotechnology, Inc.

Yahoo Finance profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 367
Headquarters: San Francisco, CA, United States
Website: vir.bio
Officers: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. President, CEO & Director
Ms. Vanina de Verneuil J.D.

SEAS

Seasonality · VIR

2019–2026 · monthly returns

Strongest month Jan +47.77%Weakest month Mar −12.15%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	23.4	22.2	-1.4	14.0	-6.6	6.8	-15.0	26.3	2.2	-1.4			+82.8%
2025	41.7	-19.3	-22.8	-5.6	-19.3	2.0	0.6	-2.6	15.6	4.4	7.7	-6.1	−17.8%
2024	-6.6	19.6	-9.9	-16.5	21.4	-13.3	14.2	-18.7	-9.3	0.0	6.3	-7.8	−27.0%
2023	16.8	-22.8	2.1	8.1	6.0	-8.0	-42.6	-10.1	-26.0	-15.4	19.7	6.0	−60.3%
2022	-18.0	-26.6	2.1	-20.9	26.8	-1.3	9.2	-14.6	-18.8	14.0	28.4	-10.3	−39.6%
2021	141.0	-3.0	-18.1	-6.9	-12.2	12.8	-24.6	44.6	-15.6	-13.3	25.7	-11.7	+56.3%
2020	111.8	74.6	-26.3	-11.0	12.0	19.9	16.6	-15.2	-15.2	-8.4	1.4	-16.0	+113.0%
2019											-15.2	5.2	−10.8%

INSD

Insider Activity · VIR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

64K shares

Sells, 6 months

25.6K shares

Net shares

+38.4K

Net change in insider shares

+0.30%

Date	Insider	Transaction	Shares	Value
Jun 8, 2026	Coughlin TimothyDirector	Stock Award(Grant) at price 0.00 per share.	16K	—
May 31, 2026	Napolitano Janet AnnDirector	Sale at price 9.45 per share.	3.2K	$30.24K
May 31, 2026	Sabatini BrentOfficer	Sale at price 9.45 per share.	379	$3.58K
May 26, 2026	Ramy Samir Farid Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	8K	—
May 26, 2026	Napolitano Janet AnnDirector	Stock Award(Grant) at price 0.00 per share.	8K	—
May 26, 2026	Sigal Charles ElliottDirector	Stock Award(Grant) at price 0.00 per share.	8K	—
May 26, 2026	Bischofberger Norbert WDirector	Stock Award(Grant) at price 0.00 per share.	8K	—
May 26, 2026	More Robert JDirector	Stock Award(Grant) at price 0.00 per share.	8K	—
May 26, 2026	Hatfield Jeffrey SDirector	Stock Award(Grant) at price 0.00 per share.	8K	—
Apr 30, 2026	Sato Vicki LeeDirector	Sale at price 10.05 per share.	22K	$221.03K
Apr 5, 2026	De Backer MarianneChief Executive Officer	Sale at price 9.16 per share.	72.6K	$664.35K
Mar 31, 2026	Sato Vicki LeeDirector	Sale at price 9.07 per share.	22K	$199.62K
Mar 22, 2026	Sabatini BrentOfficer	Sale at price 9.12 per share.	7.7K	$70.32K
Mar 1, 2026	Sato Vicki LeeDirector	Sale at price 9.50 - 9.98 per share.	22K	$209.18K
Feb 24, 2026	De Verneuil Vanina Alexandra HuardGeneral Counsel	Sale at price 9.53 - 9.82 per share.	16.8K	$164.25K
Feb 24, 2026	Eisner Mark EOfficer	Sale at price 9.53 - 9.82 per share.	3.5K	$33.95K
Feb 23, 2026	De Backer MarianneChief Executive Officer	Sale at price 9.53 per share.	14.8K	$140.72K
Feb 23, 2026	O'Byrne JasonChief Financial Officer	Sale at price 9.53 per share.	1.6K	$15.58K
Feb 23, 2026	Sabatini BrentOfficer	Sale at price 9.53 per share.	1.4K	$13.63K
Feb 23, 2026	Sato Vicki LeeDirector	Sale at price 9.75 - 10.26 per share.	42.4K	$413.37K

13F

Investors Holding VIR

latest 13F filings of 29 followed managers

Investors holding VIR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$10.4M	0.01%	1.02M	+34%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VIR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VIR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vir Biotechnology, Inc.

Seasonality · VIR

Insider Activity · VIR

Congress Trades · VIR

Investors Holding VIR

Investors Holding VIR

Congress Trades · VIR

Insider Activity · VIR

Seasonality · VIR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vir Biotechnology, Inc.

Financial Snapshot

Earnings & Dividends

News